• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Diphenylethers

N-Desbutyl-N-propyl Bumetanide (CAS No. 28395-28-0): A Comprehensive Overview

N-Desbutyl-N-propyl Bumetanide (CAS No. 28395-28-0) is a specialized derivative of the well-known diuretic bumetanide. This compound has garnered significant attention in pharmaceutical research due to its potential therapeutic applications and unique pharmacological properties. As researchers continue to explore novel diuretic compounds and renal-targeted therapies, N-Desbutyl-N-propyl Bumetanide emerges as a promising candidate for further investigation.

The chemical structure of N-Desbutyl-N-propyl Bumetanide features modifications at the nitrogen position, where the butyl group is replaced by a propyl moiety. This structural alteration influences its pharmacokinetic profile and receptor binding affinity, potentially offering advantages over the parent compound. Current studies suggest this derivative may exhibit improved target specificity or reduced off-target effects, though comprehensive clinical data remains limited.

In the context of today's pharmaceutical landscape, researchers are particularly interested in N-Desbutyl-N-propyl Bumetanide for its potential applications in precision medicine approaches. With growing emphasis on personalized diuretic therapy for conditions like heart failure and hypertension, this compound represents an important area of investigation. Its development aligns with current trends toward structure-activity relationship optimization in medicinal chemistry.

The synthesis of N-Desbutyl-N-propyl Bumetanide typically involves multi-step organic transformations starting from bumetanide precursors. Analytical characterization using techniques like HPLC, mass spectrometry, and NMR spectroscopy confirms the compound's purity and structural integrity. These quality control measures are crucial for ensuring reliable research outcomes in both in vitro and in vivo studies.

From a therapeutic perspective, preliminary research indicates N-Desbutyl-N-propyl Bumetanide may maintain the potent loop diuretic activity characteristic of its parent compound while potentially offering modified renal excretion profiles. This could have implications for patients requiring diuretic therapy with specific pharmacokinetic needs. However, comprehensive clinical trials would be necessary to fully evaluate its therapeutic potential and safety profile.

The pharmaceutical industry's growing interest in N-Desbutyl-N-propyl Bumetanide reflects broader trends in drug repurposing and derivative development. As researchers seek to optimize existing medications, compounds like this represent valuable opportunities to expand therapeutic options while building on established safety profiles. This approach aligns with current demands for cost-effective drug development strategies in the healthcare sector.

Quality standards for N-Desbutyl-N-propyl Bumetanide in research applications typically require high purity levels (>98%), as verified by advanced analytical methods. The compound is generally supplied as a white to off-white crystalline powder, with proper storage conditions being essential to maintain stability. Researchers should note that handling procedures may vary depending on specific laboratory protocols and intended applications.

Future research directions for N-Desbutyl-N-propyl Bumetanide may include detailed investigations of its molecular mechanisms, potential drug interactions, and comparative efficacy studies against standard diuretics. As the scientific community continues to explore renal sodium transport modulation and electrolyte balance management, this compound may contribute valuable insights to these important areas of medical research.

For researchers and pharmaceutical developers, N-Desbutyl-N-propyl Bumetanide represents an interesting case study in medicinal chemistry optimization. Its development pathway illustrates how strategic molecular modifications can potentially enhance therapeutic properties while maintaining core pharmacological activity. This approach has become increasingly relevant in today's competitive pharmaceutical research environment.

As with any investigational compound, thorough evaluation of N-Desbutyl-N-propyl Bumetanide through rigorous preclinical and clinical testing will be essential to determine its ultimate place in therapeutic practice. The compound's journey from laboratory synthesis to potential clinical application exemplifies the complex, multi-stage process of modern drug discovery and development.

• 55837-27-9(Piretanide)
• 32643-00-8(Bumetanide Butyl Ester)
• 28395-03-1(Bumetanide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)